Excipient Compatibility as Predicted by ASAP - Description
A Case Study. 1. Jerusha Thompson. Science of Stability 2015. October 12-14, 2015 Connecticut, US. . Getting To K. no. w Faster. 2. Outline. Introduction. Overview of Traditional Excipient Compatibility Studies. ID: 616000 Download Presentation
A Case Study. 1. Jerusha Thompson. Science of Stability 2015. October 12-14, 2015 Connecticut, US. . Getting To K. no. w Faster. 2. Outline. Introduction. Overview of Traditional Excipient Compatibility Studies.
Download Presentation - The PPT/PDF document "Excipient Compatibility as Predicted by ..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Presentation on theme: "Excipient Compatibility as Predicted by ASAP"— Presentation transcript:
Slide1
Excipient Compatibility as Predicted by ASAP
A Case Study
1
Jerusha Thompson
Science of Stability 2015
October 12-14, 2015 Connecticut, US
Slide2
Getting To Know Faster
2
Slide3
Outline
IntroductionOverview of Traditional Excipient Compatibility StudiesAccelerated Stability Assessment Program (ASAP)Case StudyAlternate Analytical TechniqueComparison of Analytical TechniquesConclusionAcknowledgement
3
Slide4
Introduction
Provide a rational for excipient selectionICH Q8(R2): Pharmaceutical DevelopmentThe compatibility of the drug substance with excipients listed should be evaluatedImpact on stability of APIRisk managementRegulatory RequirementQOS: What evidence supports compatibility between the excipients and the drug substance?
Jerusha Thompson
4
Slide5
Traditional Excipient Compatibility Studies
Binary mixture of active pharmaceutical ingredient (API) and excipient prepared in a 1:1 ratio Excipients showing incompatibility at the 1:1 ratio tested at a ratio more typical of the final formulationTwo vial types (duplicate vials for each) prepared for each drug-excipient blendAssay vial (pre-weighed for moisture)Composite vial (for additional tests)
5
Slide6
Traditional Excipient Compatibility Study
Three controlled conditions200 vials prepared for 7 excipients studied open dish
The analytical testing includes:AssayImpuritiesDescriptionLoss on Drying (LOD)Results compared to a control (API) across all time points and conditions to look for any trending Any unexplained or unexpected loss in potency, or increase in impurities over time mandated further investigationsExcipient ratio screening, at the levels typical of the final formulation.
7
Slide8
Traditional Excipient Compatibility Studies
Limitations1:1 Binary blends not representative of formulationMay not pick up on incompatibilitiesManufacturingProcessingTableting Sample LoadResourcesIncreased time-lineInconclusive resultsNot an indicator of formulation stability
8
Slide9
Accelerated Stability Assessment Plan: Excipient Compatibility Study
Rapid approach to determine incompatibilitiesMultiple prototype formulations screened simultaneouslyProvides greater understanding of drug product stabilityImpurity profileAllows rapid entry in full formulation developmentPredicts impact of container/closure on product stability
9
Slide10
ASAP: Excipient Compatibility Study
Sample count depends on study 21 samples for 3 batches testedAmebis Incubation SystemIncubation flask controls temperature/humidity
10
Slide11
Case Study
aNDA programPresence of lactose in reference listed drug (RLD)Maillard reactionChemical reaction between amine and sugarOne known degradation productSpecification limit defined by ICH Q3B(R2) and monographDrug product: oral tabletStrength: 0.5mg, 1mg, and 2mgCommercial packaging configuration: 100 and 1000 count HDPE bottleTimeline12 months to develop final formulation
11
Slide12
Case Study
API determined to be stableThree prototype formulations pressed into tabletsManufactured at bench scaleFormulation 1 approximates RLD formulation
12
Slide13
Case Study
ASAP design parameters7 samples per prototype formulationContainer closure system selected based on appropriate sized bottle for 100 tablets
13
Jerusha Thompson
Slide14
Case Study
Testing designScreening design for excipient selectionMinimal approach taken comparing three prototypesOnce prototype formulation selected and optimized then additional more robust ASAP study conducted
14
Slide15
Case Study
Stability indicating UHPLC methodReporting impurities equal or greater then 0.02% label claim2 days for analytical analyses with a developed method
Predicted results from ASAP®Prime meeting acceptance criteria of 0.2% label claimAll degradation productsPackaging assessedWith and without desiccantICH accelerated and CRTRRT 3.31 poor correlationPotential secondary degradation
ResultsFormulation 1 (RLD)Two unique unidentified degradation products observedFormulation 2Known 1 would have difficulty meeting a shelf-life of 24 months without a desiccantFailure at accelerated conditions would require additional testing at an intermediate conditionFormulation 3Highest probability of passing all conditions without desiccantStudy results will help justify the excipient and packaging selection in CMC section of submission
21
Slide22
Alternative Analytical Technique
Rapid entry into full formulation development with ASAP allows decreased timelineTraditional approach to excipient studies ~3-6 monthsASAP ~ 2-4 weeksRate limiting step can become analytical technologyStability indicating HPLC method can take time to develop~1-2 monthsResponse of degradation products to parent compound criticalQuantitative NMR (qNMR)One method for all drug productsNo method development requiredNo response of degradation product neededNo quantitative reference standard required
22
Slide23
Alternative Analytical Technique
qNMR Parameters
Pauli, G. F. et al. J. Med Chem. 2014, 57, 9220-9231
Weber, M. et al. J. Pharm. Biomed. Anal. 2014, 93, 102-110
23
Slide24
Alternative Analytical Technique
24
Slide25
Alternative Analytical Technique
Predicted results for meeting acceptance criteria of 0.2%
25
Slide26
Alternative Analytical Technique
Known 1 data for each prototype formulation analyzed using qNMR The results of the analysis predict prototype formulation 3 (Starch 1500) would have the greatest probability of meeting an acceptance criteria of 0.2% label claimAnalysis of unknown degradation products not performed during this analysisFurther optimization of extraction process necessaryBoth analytical techniques selected prototype formulation 3 as the most stable formulation
26
Slide27
Conclusion
The data generated from the excipient compatibility study predicted prototype formulation 3 would be the best candidate to move forward into full formulation developmentAnalysis of each of the prototype formulation in the ASAP study also provided an early profile of likely degradation products present in each formulationBoth analytical techniques investigating selected prototype formulation 3qNMR analysis may allow for faster determination of instabilities in a drug productThe predictions from the ASAP study will be further monitored through the project, and confirmed through traditional ICH stability studiesASAP approach to excipient compatibility testing allows faster entry into full formulation development ~2-5 month
